CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 53 enrolled
Drug / intervention
Memantinedrug
Likely dose
Memantine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03703856
NCT03703856Phase 4Completed
CompareCT.gov

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

University of California, San Diego·interventional·Posted Oct 12, 2018·Updated Apr 16, 2026

In Brief

A Phase 4 clinical trial evaluating Memantine for Alzheimer Disease. Completed, enrolled 53 participants across 1 site.

Detailed Summary

The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedOct 12, 2018
Enrollment StartJan 31, 2019
Primary CompletionJan 8, 2025
Study CompletionDec 30, 2025
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 7.7 years ago

Interventions

Memantinedrug

Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this "challenge" test, a set of "early auditory information processing memantine sensitivity" measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated.